METHOCARBAMOL

Posology Adults:

The usual dose is 2 tablets four times daily but therapeutic response has been achieved with doses as low as 1 tablet three times daily.

Elderly:

Half the maximum dose or less may be sufficient to produce a therapeutic response. Paediatric population Not recommended. Hepatically impaired In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.

Method of administration For oral use. Take the film-coated tablets with sufficient water.

g. g. lips, tongue) or the extremities (hands, fingers, feet) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Methocarbamol should be used with caution in patients with renal and hepatic insufficiency. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free’. Interference with laboratory tests Methocarbamol may cause colour interference in certain screening tests for 5- hydroxyindolacetic acid (5-HIAA) and vanillylmandelic acid (VMA)

1. • Coma or pre-coma states • Central nervous system disorders • Myasthenia gravis • Patients with a tendency to epileptic cramps